Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.

In one cohort, HERPUD1 and NLRP7 also showed statistically significant increases in responders, and although RHEBL1 did not reach statistical significance, it displayed a consistent upward trend in the responder group (Figure 2E ; Figure S4E , Supporting Information).

also in 111,027 other papers